CAMBRIDGE, Mass.--(BUSINESS WIRE)--Researchers at Molecular Insight Pharmaceuticals today announced the presentation of preclinical data on MIP-1072, a radiolabeled, small molecule molecular imaging pharmaceutical in development for diagnosis and staging of prostate cancer at the 54th annual meeting of the Society of Nuclear Medicine (SNM) in Washington, D.C. MIP-1072 is one of two development candidates for prostate cancer diagnosis that Molecular Insight plans to advance into exploratory human studies in the first half of next year. It is designed to target prostate specific membrane antigen (PSMA), a protein highly expressed by prostate tumor cells. The presentation is one of four on the company’s products and technologies to be presented at the meeting.
